Tag: Pascale Witz

November 6, 2015 Off

Sanofi and Lexicon to develop sotagliflozin (for diabetics)

By Dino Mustafić

Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.